Skip to Content

Join the 'Genvoya' group to help and get support from people like you.

Genvoya News

Fighting HIV on Multiple Fronts Might Lead to Vaccine

Posted 20 Sep 2017 by Drugs.com

WEDNESDAY, Sept. 20, 2017 – A combination antibody strategy could be the key to halting the spread of HIV, according to results from two promising animal studies. Two separate research groups completely protected their own sets of lab monkeys from HIV infection using this combination vaccination strategy, albeit in two very different ways. One group inoculated their monkeys with a "cocktail" of two HIV antibodies, while the other group genetically engineered a single antibody capable of attacking HIV in three different ways. There's just one downside: Because these antibodies are injected into the body rather than naturally created by the immune system, people will have to receive shots on a regular basis to retain their protection against the AIDS-causing virus. The strategy focuses on broadly neutralizing HIV antibodies, a type of antibody that attaches to the virus and prevents it ... Read more

Related support groups: HIV Infection, Pre-Exposure Prophylaxis, Atripla, Incivek, Truvada, Stribild, Genvoya, Complera, Victrelis, Baraclude, Viread, Norvir, Prezista, Telaprevir, Kaletra, Tenofovir, Ritonavir, Entecavir, Boceprevir, Hepsera

Could a Monetary Perk Help Keep HIV Patients on Their Meds?

Posted 22 Jun 2017 by Drugs.com

WEDNESDAY, June 21, 2017 – There are mixed results from a new study on the use of monetary rewards to help boost the odds that HIV-infected patients will enter care, and take their meds as directed. The study, conducted at HIV clinics in New York City and Washington, D.C., found that financial incentives such as gift cards could improve the likelihood that HIV patients would take antiretroviral medications that suppress the AIDS-causing virus. But the effect was modest in patients already receiving care, and the gift cards had little effect on increasing the number of new HIV-positive patients who got treated, the study authors said. Still, lead author Dr. Wafaa El-Sadr called the results "encouraging" and said they "should motivate efforts to pursue the further assessment of using financial incentives in HIV treatment programs and to determine their potential impact when scaled up." ... Read more

Related support groups: Harvoni, HIV Infection, Pre-Exposure Prophylaxis, Atripla, Epclusa, Incivek, Truvada, Triumeq, Stribild, Zepatier, Complera, Genvoya, Victrelis, Baraclude, Viread, Norvir, Prezista, Kaletra, Telaprevir, Tenofovir

Americans With HIV Staying on Lifesaving Meds Longer

Posted 31 May 2017 by Drugs.com

WEDNESDAY, May 31, 2017 – More Americans with HIV are sticking with medications that turn a fatal disease into a manageable condition, a new study shows. "This represents a lot of people who are not dying and not infecting others," said study corresponding author Ira Wilson, chair of Brown University's Health Services Policy and Practice Department, in Providence, R.I. "These differences represent tremendous, very real benefit," he added in a university news release. While there have been significant increases in how long HIV patients take their medications, many people still stop taking the drugs after a few years, the researchers cautioned. In the study, the researchers analyzed data from nearly 43,600 Medicaid patients in 14 states from 2001 to 2010, and found the length of time patients kept taking antiretroviral medications increased more than 50 percent. In 2001-2003, half of ... Read more

Related support groups: Harvoni, HIV Infection, Pre-Exposure Prophylaxis, Atripla, Epclusa, Incivek, Truvada, Triumeq, Stribild, Zepatier, Complera, Genvoya, Victrelis, Baraclude, Viread, Norvir, Prezista, Telaprevir, Kaletra, Tenofovir

Doctors Seeing More HIV Patients With Multidrug Resistance

Posted 1 Dec 2016 by Drugs.com

THURSDAY, Dec. 1, 2016 – A significant number of people with HIV have strains of the AIDS-causing virus that are resistant to both older and newer drugs, researchers report. The researchers looked at 712 HIV patients worldwide whose infection was not controlled by antiretroviral drugs. They found that 16 percent of patients whose infection was resistant to modern drugs had HIV mutations linked with resistance to older drugs called thymidine analogues. Among patients whose HIV had this mutation, 80 percent were also resistant to tenofovir, the main drug in most modern HIV treatment and prevention programs, the researchers reported. The findings were published in the Nov. 30 issue of The Lancet Infectious Diseases journal. "We were very surprised to see that so many people were resistant to both drugs, as we didn't think this was possible," study lead author Ravi Gupta, of University ... Read more

Related support groups: Harvoni, HIV Infection, Pre-Exposure Prophylaxis, Sovaldi, Atripla, Epclusa, Incivek, Truvada, Triumeq, Stribild, Zepatier, Genvoya, Complera, Sofosbuvir, Victrelis, Baraclude, Viread, Norvir, Prezista, Tenofovir

HIV Infection Seems to Affect Nervous System

Posted 13 Jun 2016 by Drugs.com

MONDAY, June 13, 2016 – Many newly infected HIV patients experience neurological problems, but they tend to be mild and they subside after antiretroviral drugs are given, a new study finds. "We were surprised that neurologic findings were so pervasive in participants diagnosed with very recent HIV infection," said study author Dr. Joanna Hellmuth. She is a clinical fellow in the department of neurology at the University of California, San Francisco (UCSF). "While the findings were mild, it is clear that HIV affects the nervous system within days of infection," she said in a university news release. "Since the majority of these neurologic issues were resolved with treatment, our study reinforces recommendations that people at risk for HIV test often and start antiretroviral treatment immediately if they are infected," Hellmuth added. Among 139 people in Thailand infected with HIV three ... Read more

Related support groups: Peripheral Neuropathy, Harvoni, HIV Infection, Pre-Exposure Prophylaxis, Atripla, Incivek, Truvada, Triumeq, Stribild, Zepatier, Autonomic Neuropathy, Complera, Genvoya, Victrelis, Baraclude, Viread, Norvir, Prezista, Kaletra, Daklinza

HIV Decline Falls Short of U.S. 5-Year Goal

Posted 6 May 2016 by Drugs.com

FRIDAY, May 6, 2016 – Although HIV infection and transmission rates in the United States declined over the past five years, they fell short of White House targets, a new study finds. Between 2010 and 2015, new HIV infections decreased 11 percent and transmission of the AIDS-causing virus declined 17 percent, far less than the goals set in 2010 as part of the U.S. National HIV/AIDS Strategy (NHAS), researchers said. The NHAS goals for 2015 were reductions of 25 percent for new HIV infections and 30 percent declines in HIV transmission. "Even though we missed the goals by a sizable margin, it's promising to see that we made important progress in reducing rates of HIV infection and transmission," said lead study author Robert Bonacci. He is a fourth-year medical student at the University of Pennsylvania Perelman School of Medicine. The aim was to lower the persistent HIV infection rate ... Read more

Related support groups: Harvoni, HIV Infection, Pre-Exposure Prophylaxis, Atripla, Incivek, Truvada, Triumeq, Stribild, Zepatier, Complera, Genvoya, Victrelis, Baraclude, Viread, Norvir, Prezista, Kaletra, Telaprevir, Tenofovir, Ritonavir

Prenatal Use of HIV Drug May Slow Child's Development Slightly

Posted 23 Feb 2016 by Drugs.com

TUESDAY, Feb. 23, 2016 – A drug used to prevent mother-to-child HIV transmission during pregnancy may slow language development slightly in children, a new study suggests. Researchers followed more than 900 infants who were born to HIV-positive mothers but were not infected by the AIDS-causing virus. All of the mothers took antiretroviral drugs during pregnancy. Some of the treatment regimens included a drug called atazanavir (Reyataz), while others did not. The infants underwent a standard test of development at 1 year of age. The 167 infants whose mothers took atazanavir during pregnancy had slightly lower language and social development scores than the 750 infants whose mothers did not take the drug. But the study only showed an association between atazanavir and language delays in children, and did not prove a cause-and-effect link. And the difference in social development scores ... Read more

Related support groups: Harvoni, HIV Infection, Pre-Exposure Prophylaxis, Atripla, Incivek, Truvada, Triumeq, Stribild, Complera, Genvoya, Victrelis, Baraclude, Viread, Norvir, Prezista, Kaletra, Telaprevir, Tenofovir, Ritonavir, Viekira Pak

Vaginal Ring Offers Some Protection Against HIV, Study Says

Posted 23 Feb 2016 by Drugs.com

MONDAY, Feb. 22, 2016 – An insertable vaginal ring containing a month's supply of a continuous-release HIV prevention drug reduced the risk of HIV in African women by at least 27 percent, a new study found. The ring works by slowly and continuously delivering a highly localized and controlled amount of the antiretroviral medication dapivirine. This drug aims to halt the ability of HIV – the virus that causes AIDS – to replicate inside a healthy cell. The goal: to prevent HIV infection, rather than treat it, the researchers said. "These results come after a number of challenging years in the effort to find ways to improve HIV control," said study lead author Dr. Jared Baeten, a professor in the departments of global health, medicine and epidemiology at the University of Washington in Seattle. "But while the dapivirine vaginal ring isn't commercially available yet, I'm really very ... Read more

Related support groups: Harvoni, HIV Infection, Pre-Exposure Prophylaxis, Atripla, Incivek, Truvada, Triumeq, Stribild, Complera, Genvoya, Viral Infection, Victrelis, Baraclude, Viread, Norvir, Prezista, Telaprevir, Kaletra, Tenofovir, Viekira Pak

CDC: Black Americans With HIV Still Less Likely to Get Ongoing Medical Care

Posted 5 Feb 2016 by Drugs.com

FRIDAY, Feb. 5, 2016 – While HIV diagnoses dropped significantly over the past decade in the United States, blacks with HIV are less likely than whites or Hispanics to receive routine, ongoing care, according to the U.S. Centers for Disease Control and Prevention. From 2005 to 2014, annual HIV diagnoses fell 19 percent in the United States. Infections among black women dropped 42 percent during this period. Despite this progress in the fight against HIV, racial disparities persist, the CDC found. While black people make up 12 percent of the U.S. population, they accounted for nearly half of all HIV diagnoses in 2014. "CDC has been working for many years to eliminate the HIV disparities that exist within the black community," Dr. Eugene McCray, director of the CDC's Division of HIV/AIDS Prevention, said in an agency news release. "While we are seeing signs of success, we must continue ... Read more

Related support groups: Harvoni, HIV Infection, Pre-Exposure Prophylaxis, Atripla, Tamiflu, Incivek, Truvada, Triumeq, Stribild, Genvoya, Complera, Victrelis, Baraclude, Viread, Norvir, Prezista, Telaprevir, Kaletra, Tenofovir, Ritonavir

Resistance to HIV Drug Growing, Study Finds

Posted 29 Jan 2016 by Drugs.com

FRIDAY, Jan. 29, 2016 – HIV resistance to the antiretroviral drug tenofovir (Viread) is increasingly common, a new study finds. The researchers said their finding is surprising and alarming because the drug plays a major role in treating and preventing infection with HIV, the virus that causes AIDS. "Tenofovir is a critical part of our armamentarium against HIV, so it is extremely concerning to see such a high level of resistance to this drug," study author Dr. Ravi Gupta, from the department of infection and immunity at University College London in England, said in a university news release. "It is very potent drug with few side effects, and there aren't any good alternatives that can be deployed using a public health approach. Tenofovir is used not only to treat HIV but also to prevent it in high-risk groups, so we urgently need to do more to combat the problem of emerging ... Read more

Related support groups: HIV Infection, Pre-Exposure Prophylaxis, Atripla, Truvada, Stribild, Genvoya, Complera, Viral Infection, Viread, Tenofovir, Emtricitabine/lopinavir/ritonavir/tenofovir, Emtricitabine/rilpivirine/tenofovir, Cobicistat/elvitegravir/emtricitabine/tenofovir, Efavirenz/Emtricitabine/Tenofovir, Emtricitabine/nelfinavir/tenofovir, Emtricitabine/Tenofovir

HIV Can Persist in Body Despite Drug Therapy

Posted 27 Jan 2016 by Drugs.com

WEDNESDAY, Jan. 27, 2016 – Even when blood tests of HIV patients on antiretroviral drugs show no sign of the AIDS-causing virus, it can still be replicating in lymphoid tissue, researchers report. The study offers important new insight into how HIV persists in the body despite treatment with the powerful drugs, according to the team of international researchers led by Northwestern University's Feinberg School of Medicine in Chicago. To reach their finding, they examined viral sequences in samples of lymph node and blood cells from three HIV-infected patients who had no detectable virus in their blood. And what they found was that a viral reservoir in lymphoid tissue, which scientists believed held long-lived infected cells in a resting state, was being constantly replenished with infected cells. "The challenge is to deliver drugs at clinically effective concentrations to where the ... Read more

Related support groups: Harvoni, HIV Infection, Pre-Exposure Prophylaxis, Sovaldi, Atripla, Incivek, Truvada, Triumeq, Stribild, Complera, Genvoya, Sofosbuvir, Victrelis, Baraclude, Viread, Diagnosis and Investigation, Norvir, Prezista, Kaletra, Telaprevir

FDA Approves Genvoya (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) for HIV

Posted 5 Nov 2015 by Drugs.com

The U.S. Food and Drug Administration today approved Genvoya (a fixed-dose combination tablet containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) as a complete regimen for the treatment of HIV-1 infection in adults and pediatric patients 12 years of age and older. The CDC estimates that 1.2 million persons ages 13 years and older are living with HIV infection, and that more than another 150,000 persons in this age range have HIV but are unaware of their infection. Over the past decade, the number of people living with HIV has increased, while the annual number of new HIV infections has remained relatively stable. “Today’s approval of a fixed dose combination containing a new form of tenofovir provides another effective, once daily complete regimen for patients with HIV-1 infection,” said Edward Cox, M.D., director of the Office of Antimicrobial Products in th ... Read more

Related support groups: HIV Infection, Stribild, Genvoya, Viread, Tenofovir, Elvitegravir, Emtriva, Tybost, Cobicistat, Vitekta, Emtricitabine, Cobicistat/elvitegravir/emtricitabine/tenofovir Alafenamide, Cobicistat/elvitegravir/emtricitabine/tenofovir

Ask a Question

Further Information

Related Condition Support Groups

HIV Infection

Genvoya Patient Information at Drugs.com